Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
This is a pilot study of biomarker evaluation and safety of pre-incisional ketorolac for patients undergoing surgical resection for non-small cell lung cancer and renal cell carcinoma. There is significant promise in the use of preoperative ketorolac to decrease the inflammatory response after surgical resection of tumors, thereby potentially reducing the risk of distant metastatic tumor spread and improving survival. This research will advance scientific knowledge by studying the safety of a preoperative dose of ketorolac prior to major surgical resection, which needs to be assessed prior to proceeding with a larger phase II study designed to evaluate traditional efficacy endpoints such as recurrence and overall survival.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Mar 4, 2025 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Other
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Emory University
- Interventions being studied
- Drug: Preoperative Ketorolac
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Pathology-proven or suspected stage 1 or 2 NSCLC and Stage 3 tumor stage 3, node stage 0 (T3N0) RCC, that require surgical resection as the treatment of choice
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Ability to understand and the willingness to sign an informed written consent
- Individuals with pure lung ground-glass opacity (GGO) lesions or mixed GGO with \<50% solid component
- Patients undergoing pneumonectomy
- History of cancer in the 3 years prior to surgery (except for basal-cell carcinoma of the skin or cervical neoplasia).
- Contraindication for NSAIDs, including peptic ulcer disease, preoperative chronic kidney disease with estimated glomerular filtration rate (eGFR) \<45, allergies or intolerance to NSAIDs, coagulation disorder, or age \> 80 years
- Having taken an NSAID within 5 days prior to surgery
- Immunocompromised status
- Refusal or inability to understand the protocol and consent form or to receive follow-up in line with the recommendations
- Preoperative hemoglobin \< 9.0
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Emory University Hospital MidtownAtlanta, Georgia
- Emory ClinicAtlanta, Georgia
- Emory University HospitalAtlanta, Georgia
- Winship Cancer InstituteAtlanta, Georgia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 4, 2025. Always confirm current availability with the study team.